Navigation Links
The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Date:3/18/2009

AURORA, Colo., March 18 /PRNewswire/ -- Pharmatech Oncology has been selected by the Fitzsimons Redevelopment Authority to be a preferred vendor to the Colorado Science + Technology Park at Fitzsimons. The Technology Park is home to 25 pharmaceutical and biotechnology companies. The majority of the companies are in the research stage with a select number of companies expanding their research on commercial products. Pharmatech Oncology was chosen as a preferred vendor for its Contract Research, Site Management, and Data Management services within the realm of managing clinical research trials.

Forest City Science + Technology Group, in partnership with the Fitzsimons Redevelopment Authority, is developing the 184-acre Colorado Science + Technology Park at Fitzsimons. The synergy created by the research and development from the private bioscience companies, along with the clinical research endeavors of the University of Colorado Hospital and The Children's Hospital, allows for collaboration, cooperation and scientific advancement. "Colorado has experienced a considerable amount of growth in this industry and we are very fortunate to have Pharmatech Oncology helping contribute to the Fitzsimons campus becoming a world-class research campus," affirms Vicki Jenings, Director of Business Relations for the Fitzsimons Redevelopment Authority.

Rob Bohacs, Director of Business Development, Pharmatech Oncology, states that "Pharmatech Oncology is privileged to be a preferred vendor to the Colorado Science + Technology Park and to serve the companies within the life sciences cluster. It's exciting to witness the expansion of the Technology Park, as well as the significant medical research that is being conducted by its affiliated companies."

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types of research aside from strictly oncology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

About The Fitzsimons Redevelopment Authority/Colorado Science + Technology Park at Fitzsimons:

The Fitzsimons Redevelopment Authority oversees the commercial development of the Fitzsimons Life Science District, ensuring its legacy as the center of life science pursuits in the Rocky Mountain Region. The Colorado Science + Technology Park at Fitzsimons is a 184-acre medical and research park located in the Life Science District, which is being developed by Forest City Science + Technology Group, a leading developer of life science campuses across the country. Companies that locate in the park will benefit from close proximity to the talent and core laboratory facilities of the University of Colorado Hospital, University of Colorado Denver research and education facilities at the Anschutz Medical Campus, The Children's Hospital and future Veterans Affairs Hospital.

Key Words: Oncology, Clinical Trials, Cancer, Patients, Contract Research, Site Management, Data Management, Research, Network, Fitzsimons


'/>"/>
SOURCE Pharmatech Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
2. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
3. USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness
4. The Australian Research Council Selects Scopus for the Evaluation of the Australian Research Landscape
5. Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009
6. The IN VIVO Blog Selects First Annual Deal of the Year
7. Tully-Wihr Company Selects Web-Based Allscripts Electronic Health Record for 100 Northern California Physicians
8. WuXi AppTec Selects H-Cube from ThalesNano for Laboratory-based Hydrogenation
9. Community Care Physicians Selects Allscripts Practice Management System for 190 Physicians in New York Capitol Region
10. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
11. Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017  Former NFL players who had repeated ... later in life, according to a preliminary study released today ... 69th Annual Meeting in Boston , April ... complex movements where the muscles and nerves work together, like ... ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... Corporation ventured outside of weighing equipment with the goal of expanding the reach ... mind, the line of Starter water analysis meters were introduced into the market ...
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
Breaking Biology News(10 mins):